1. Immune checkpoint inhibitors’ combination therapy as first-line treatment in advanced esophageal squamous cell carcinoma: a meta-analysis

   • Dianhe Li
   • Ling Tang
   • Yan He

   Review 25 June 2022 Pages: 933 - 939

   

2. Anti-PD-1-based immunotherapy plus lenvatinib to treat advanced gallbladder cancer in the elderly: a case series and review of current literature

   • Lantian Wang
   • Kezhong Tang
   • Wenjie Lu

   Review 27 June 2022 Pages: 941 - 950

   

3. Circulating metabolite biomarkers: a game changer in the human prostate cancer diagnosis

   • Sabareeswaran Krishnan
   • Shruthi Kanthaje
   • Chandrahas Koumar Ratnacaram

   Review 28 June 2022 Pages: 951 - 967

   

4. Clinical outcomes of PD-1/PD-L1 inhibitors in patients with advanced hepatocellular carcinoma: a systematic review and meta-analysis

   • Wen Wen
   • Yong Zhang
   • Yingshuang Chen

   Review 30 June 2022 Pages: 969 - 978

   

5. Roles of circular RNAs in regulating the development of glioma

   • Jianing Fan
   • Yangyang Wang
   • Yu Li

   Review 01 July 2022 Pages: 979 - 993

   

6. Comparison of clinical characteristics, treatment efficacy and survival in patients with newly diagnosed multiple myeloma with single- versus multi-site extramedullary invasion

   • Yongfeng Zhao
   • Fuling Zhou

   Original Article – Clinical Oncology 25 February 2022 Pages: 995 - 1006

   

7. Mismatch repair deficiency, chemotherapy and survival for resectable gastric cancer: an observational study from the German staR cohort and a meta-analysis

   • T. Stolze
   • S. Franke
   • M. Venerito

   Original Article – Clinical Oncology Open access 25 February 2022 Pages: 1007 - 1017

   

8. The genomic characteristics of RET fusion positive tumors in Chinese non-small cell lung cancer (NSCLC) patients

   • Guowu Wu
   • Longhua Guo
   • Shifu Chen

   Original Article – Clinical Oncology Open access 26 February 2022 Pages: 1019 - 1028

   

9. Oncological outcomes of squamous cell carcinoma of the cervical esophagus treated with definitive (chemo-)radiotherapy: a systematic review and meta-analysis

   • Armando De Virgilio
   • Andrea Costantino
   • Giuseppe Spriano

   Original Article – Clinical Oncology 02 March 2022 Pages: 1029 - 1041

   

10. BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma: a real-life experience

    • Vittorio Stefoni
    • Lisa Argnani
    • Pier Luigi Zinzani

    Original Article – Clinical Oncology Open access 03 March 2022 Pages: 1043 - 1047

    

11. Response prediction in patients with gastric and esophagogastric adenocarcinoma under neoadjuvant chemotherapy using targeted gene expression analysis and next-generation sequencing in pre-therapeutic biopsies

    • Karsten Kleo
    • Vladimir M. Jovanovic
    • Severin Daum

    Original Article – Clinical Oncology Open access 05 March 2022 Pages: 1049 - 1061

    

12. Pulmonary neuroendocrine tumors: study of 266 cases focusing on clinicopathological characteristics, immunophenotype, and prognosis

    • Shuwen Zhang
    • Jingjing Chen
    • Jian Feng

    Original Article – Clinical Oncology Open access 06 March 2022 Pages: 1063 - 1077

    

13. A virtual dance sport class for cancer patients: the trainer perspective

    • Christian Keinki
    • Ivonne Rudolph
    • Jutta Hübner

    Original Article – Clinical Oncology Open access 07 March 2022 Pages: 1079 - 1083

14. A propensity score–matched analysis of breast-conserving surgery plus whole-breast irradiation versus mastectomy in breast cancer

    • Francesca Magnoni
    • Giovanni Corso
    • Paolo Veronesi

    Original Article – Clinical Oncology 07 March 2022 Pages: 1085 - 1093

    

15. Robotic stereotactic body radiotherapy for the management of adrenal gland metastases: a bi-institutional analysis

    • Felix Ehret
    • David Kaul
    • Alexander Muacevic

    Original Article – Clinical Oncology Open access 15 March 2022 Pages: 1095 - 1101

    

16. Optimizing the tumor shrinkage threshold for evaluating immunotherapy efficacy for advanced non-small-cell lung cancer

    • Wei Du
    • Chen Chen
    • Shaodong Hong

    Original Article – Clinical Oncology 18 March 2022 Pages: 1103 - 1113

    

17. Characteristics and survival of primary vaginal malignancy: an analysis of the German nationwide cancer registry data

    • Dirk Michael Forner

    Original Article – Clinical Oncology 21 March 2022 Pages: 1115 - 1122

    

18. Impact of omitting fluorouracil from FOLFIRI plus bevacizumab as second-line chemotherapy for patients with metastatic colorectal cancer

    • Yuki Matsubara
    • Toshiki Masuishi
    • Kei Muro

    Original Article – Clinical Oncology 22 March 2022 Pages: 1123 - 1129

    

19. Safety and effectiveness of aflibercept in combination with FOLFIRI in Korean patients with metastatic colorectal cancer who received oxaliplatin-containing regimen

    • Seung-Hoon Beom
    • Jong Gwang Kim
    • Dong Han Kim

    Original Article – Clinical Oncology 27 March 2022 Pages: 1131 - 1143

    

20. A phase 1 study of IDH305 in patients with IDH1^R132-mutant acute myeloid leukemia or myelodysplastic syndrome

    • Courtney D. DiNardo
    • Andreas Hochhaus
    • Andrew H. Wei

    Original Article – Clinical Oncology 30 March 2022 Pages: 1145 - 1158

    

21. Programmed death receptor ligand-2 (PD-L2) bearing extracellular vesicles as a new biomarker to identify early triple-negative breast cancer patients at high risk for relapse

    • Oliver Hoffmann
    • Sebastian Wormland
    • Vera Rebmann

    Original Article – Clinical Oncology Open access 02 April 2022 Pages: 1159 - 1174

    

22. Correlation analysis between androgen receptor and the clinicopathological features and prognosis of mammary Paget’s disease

    • Yang Wu
    • Shanshan Sun
    • Yanni Song

    Original Article – Clinical Oncology 02 April 2022 Pages: 1175 - 1184

    

23. Anti-angiogenic therapy for advanced primary pulmonary lymphoepithelioma-like carcinoma: a retrospective multicenter study

    • Hejing Bao
    • Ling Zhen Ma
    • Shudong Ma

    Original Article – Clinical Oncology Open access 04 April 2022 Pages: 1185 - 1193

    

24. Current clinical practice and outcome of neoadjuvant chemotherapy for early breast cancer: analysis of individual data from 94,638 patients treated in 55 breast cancer centers

    • O. Ortmann
    • J.-U. Blohmer
    • for 55 breast cancer centers certified by the German Cancer Society

    Original Article – Clinical Oncology Open access 05 April 2022 Pages: 1195 - 1209

    

25. Clinical implications of ctDNA for EGFR-TKIs as first-line treatment in NSCLC

    • Xiao Liang
    • Wei Zhang
    • Renhua Guo

    Original Article – Clinical Oncology 05 April 2022 Pages: 1211 - 1220

    

26. Can whole-body MRI replace CT in management of metastatic testicular cancer? A prospective, non-inferiority study

    • Solveig Kärk Abildtrup Larsen
    • Vibeke Løgager
    • Erik Morre Pedersen

    Original Article – Clinical Oncology 07 April 2022 Pages: 1221 - 1230

    

27. Guideline adherence and implementation of tumor board therapy recommendations for patients with gastrointestinal cancer

    • Alina Krause
    • Gertraud Stocker
    • Maren Knödler

    Original Article – Clinical Oncology Open access 08 April 2022 Pages: 1231 - 1240

    

28. Expression of DNA mismatch repair proteins in melanoma patients treated with immune checkpoint inhibitors

    • T. Gambichler
    • C. Finis
    • L. Susok

    Original Article – Clinical Oncology Open access 13 April 2022 Pages: 1241 - 1247

    

29. Systemic inflammation with sarcopenia predicts survival in patients with gastric cancer

    • Yu-Ying Liu
    • Guo-Tian Ruan
    • Han-Ping Shi

    Original Article – Clinical Oncology 18 April 2022 Pages: 1249 - 1259

    

30. Gastric cancer in the pediatric population, a multicenter cross-sectional analysis of presentation and coexisting comorbidities

    • Thomas M. Attard
    • Uraizee Omar
    • Mike A. Thomson

    Original Article – Clinical Oncology 18 April 2022 Pages: 1261 - 1272

    

31. KRAS mutation as a predictor of insufficient trastuzumab efficacy and poor prognosis in HER2-positive advanced gastric cancer

    • Keitaro Shimozaki
    • Eiji Shinozaki
    • Kensei Yamaguchi

    Original Article – Clinical Oncology 19 April 2022 Pages: 1273 - 1283

    

32. Antibiotic therapy is associated with an increased incidence of cancer

    • Christoph Roderburg
    • Sven H. Loosen
    • Karel Kostev

    Original Article – Clinical Oncology Open access 19 April 2022 Pages: 1285 - 1293

    

33. LncRNA UCA1 promoted cisplatin resistance in lung adenocarcinoma with HO1 targets NRF2/HO1 pathway

    • Wenjing Shi
    • Liqun Ling
    • Yumin Wang

    Research 06 July 2022 Pages: 1295 - 1311

    

34. The survival analysis and feasibility study of Pars Plana Vitrectomy (PPV) in the treatment of retinoblastoma

    • Jianing Mou
    • Lei Yang
    • Xin Ni

    Research 10 November 2022 Pages: 1313 - 1318

    

35. Deviating HER2 test results in gastric cancer: analysis from the prospective multicenter VARIANZ study

    • Katharina Kolbe
    • Ivonne Haffner
    • Florian Lordick

    Research Open access 27 August 2022 Pages: 1319 - 1329

    

36. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) in patients with peritoneal surface malignancies (PSM): a prospective single-center registry study

    • B. Jansen-Winkeln
    • J. Eberth
    • R. Thieme

    Research Open access 13 December 2022 Pages: 1331 - 1341

    

37. Study protocol: the OptiScreen-Study: optimized psycho-oncological care—from screening to intervention

    • Tanja Zimmermann
    • Lara Dreismann
    • Arndt Vogel

    Research Open access 27 September 2022 Pages: 1343 - 1354

    

38. Correction: LncRNA UCA1 promoted cisplatin resistance in lung adenocarcinoma with HO1 targets NRF2/HO1 pathway

    • Wenjing Shi
    • Liqun Ling
    • Yumin Wang

    Correction 03 January 2023 Pages: 1355 - 1355

39. Pembrolizumab for all

    • Myung S. Kim
    • Vinay Prasad

    Correspondence Open access 22 October 2022 Pages: 1357 - 1360

    

40. Patient characteristics and preferences for a surgical prehabilitation program design: results from a pilot survey

    • Usha Gurunathan
    • Oystein Tronstad
    • Christopher Stonell

    Correspondence 25 October 2022 Pages: 1361 - 1367

41. Reply to Letter to the Editor regarding “Oncological outcomes of squamous cell carcinoma of the cervical esophagus treated with definitive (chemo‐)radiotherapy: a systematic review and meta‐analysis”

    • Armando De Virgilio
    • Andrea Costantino
    • Giuseppe Spriano

    Correspondence 29 October 2022 Pages: 1369 - 1371